Clinical Trial Update: Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating the safety of a single 5 mg dose of hLF1-11 in autologous hematopoietic stem cell transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Mycoses

Drugs mentioned

• hLF1-11 (hLF1-11)

Snippet

Sponsor: AM-Pharma | Conditions: Hematopoietic Stem Cell Transplantation, Bacterial Infections and Mycoses | Phase 1, Phase 2 | Status: COMPLETED